“The Court’s decision confirms our belief that the fundamental intellectual property covering our revolutionary V.A.C.® technology is valid and enforceable,” said Catherine Burzik, KCI’s president and chief executive officer. “KCI will continue to enforce its intellectual property rights which allow us to invest in new technologies that help millions of patients around the world. We remain committed to new product offerings and improvements in the areas of negative pressure and V.A.C. therapy, which we expect to launch in the coming months.”
